Research, develop, manufacture, and commercialize pharmaceuticals primarily focused on dermatology. Now — the numbers.
This is an established company with proven profits.
Average growth of 8% a year over the last 4 years. Red columns mark years that ended in a loss.
The two sides balance each other out — the picture is neither a safety net nor an alarm.
The market pays 62.3× for every dollar this company earns in a year — a price that already assumes things go well.
No analyst target is on record for this company.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
It pays out $0.22 per share each year — regular cash for whoever holds the stock.
The company’s market value is 62 times its annual profit. Even a small disappointment could hit the price hard.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.